ADVERTISEMENT
ADVERTISEMENT
Biotech investing heats up amid IPO surge
Investors warned that the cycle may repeat past patterns, with weaker companies eventually entering the market
-
1759953093.png)
Staff Reporter - Thu, 30, Apr 2026
- 16:19 EDT
- 16
Speakers of the biopharma investing panel / USAIC
Boston, April 30 A renewed surge in biotech IPOs, strong drug launches and aggressive dealmaking by large pharmaceutical companies are reshaping the risk-reward equation for investors, even as concerns persist over valuation cycles and long-term returns, top industry leaders from the pharma sector said.
At the USA–India Chamber of Commerce’s BioPharma & Healthcare Summit, investors and analysts said the current market shows signs of a powerful rebound after a prolonged downturn, with capital flowing back into high-quality biotech companies.
This post is for paying subscribers only
SUBSCRIBE NOW
ADVERTISEMENT
ADVERTISEMENT
E Paper
Video
Comments
Start the conversation
Become a member of New India Abroad to start commenting.
Sign Up Now
Already have an account? Login